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Conclusions
The aim of this systematic review is to establish the most effective stop smoking intervention approach
for smokers with COPD. The search strategy included the electronic databases MEDLINE, EMBASE,
AMED, PsycINFO, DARE, Cochrane Library, and CINAHL, between January 2006 and January 2010.
References of the included studies were also screened for additional papers, and further hand searches
were conducted. The selection criteria included randomized controlled trials or quasi-randomized con-
trolled trials with at least one subject group diagnosed with COPD. Two independent reviewers re-
viewed the included studies, using a quality assessment form developed from the selection criteria.
Divergence of quality assessment scores was resolved by the 2 reviewers agreeing on a score. The 4
studies selected indicate that psychosocial interventions combined with pharmacotherapy are effective
in smoking cessation at 12 months post-intervention, although the effect is not statistically significant,
due to small sample size and heterogeneity between the studies (odds ratio 2.35, 95% CI 0.25–21.74,).
However, despite this medium effect size, due to a lack of universal use of pharmacotherapies in most
of the studies, it makes a definitive comparison of efficacy difficult to determine. This review also shows
the effectiveness of psychosocial treatment for people with or without COPD symptoms at 12 months,
although the effect of disease severity is not clear. This review also highlights the difficulty of maintain-
ing attendance at community-based locations, compared to acute or research settings. Key words: COPD;
psychosocial interventions; pharmacotherapy. [Respir Care 2013;58(11):1955–1962. © 2013 Daedalus Enterprises]
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Introduction
In 2007 the World Health Organization estimated that
COPD affected 210 million people, and reported that in
2005 3 million people had died of COPD, corresponding
to 5% of all global deaths.1 In 2002, Mannino2 estimated
that by 2020 this disease would be the 5th largest cause of
disability-adjusted life-years worldwide. More recently the
World Health Organization predicted that by 2030 this
disease will be the third leading cause of death world-
wide.1 Not all of these cases will be directly attributable to
smoking, but smoking will be the primary cause.
In the United Kingdom nearly 900,000 people have been
diagnosed with COPD, as cited by the National Health
Service, 2009.3 However, the United Kingdom National
Health Service (2009) estimates that the majority of peo-
ple with COPD are unaware of their condition and that the
real figure is approximately 3 million people in the United
Kingdom, with older people more likely to develop COPD.
Smoking Cessation and COPD
The National Institute for Health and Clinical Excel-
lence 2004 quick reference guide, Chronic Obstructive
Pulmonary Disease: Management of Chronic Pulmonary
Disease in Adults in Primary and Secondary Care,4 rec-
ommends that all COPD patients who smoke should be
encouraged to stop at every opportunity, and recommends
pharmacotherapy combined with a behavioral support pro-
gram. However, while the guidelines are set out by the
Department of Health5 on supporting smokers in the gen-
eral population to stop smoking, no guidance is yet avail-
able on the most effective way to support this chronic
disease group in stopping smoking.
Many studies have found that this group differs from the
general population in ways that affect their attempts at and
success in stopping smoking. Some of these differences
include the type of smokers they are,5 their beliefs about
how their smoking behavior relates to their COPD,6 and
the effect of a chronic disease on their psychological and
emotional well-being.7 These factors need to be consid-
ered when designing stop-smoking interventions.
Perception of the etiology of the illness is an important
factor in the decision to quit smoking. Walters and Cole-
man found that patients who attribute their respiratory
symptoms to smoking are 8 times (95% CI 3.0–23.3) more
likely to believe that their health will improve if they stop
smoking, and 6 times (95% CI 1.4–23.3) more likely to
intend to stop smoking.7
A key factor for patients with chronic diseases is ad-
herence to treatment and long-term maintenance of the
recommended behavior changes.8,9 They attribute this to a
range of factors, including patients’ perception of their
disease, type of treatment or medication, the quality of
patient-provider communication, the social environment,
and the level of anxiety and depression in patients with
COPD, although estimates of prevalence vary.
A combination of these factors is associated with lower
self-efficacy and impaired overall health status, such as
dyspnea, and loss and grief associated with the disability
of COPD.8,10 Stage et al11 reported that depression is com-
mon in COPD patients, with around 40% being affected
with clinical depression. Despite these findings, it is not
always possible to identify the exact cause when diagnos-
ing depression in COPD patients, because of common
symptoms present in both COPD and depression, such as
fatigue and altered sleep patterns.8 It is difficult to quantify
how many people with COPD continue to smoke after
diagnosis. However, clinical studies of medications for
COPD treatment have reported figures ranging between
38% and 43% of patients with moderately severe to severe
COPD continuing to smoke.12,13
Attempts to identify the most effective approach for this
group to stop smoking have been made in previous sys-
tematic reviews, and have included a combination of be-
havioral support and nicotine replacement therapy (NRT)
or alternative pharmacotherapies such as bupropion, va-
renicline, and nortriptyline as the most effective successful
cessation interventions in this population. However, it is
not clear whether, and if so how, the intervention to sup-
port an individual with COPD should differ from that of-
fered to smokers from the general population.
In their review of 5 studies undertaken between 1991
and 2001, Wagena et al14 concluded that combining psy-
chosocial interventions and pharmacologic interventions
resulted in better outcomes than either no intervention or
psychosocial interventions alone. This latter finding of the
lack of evidence to support the effectiveness of any psy-
chosocial intervention alone for smokers with COPD was
due to a lack of high-quality studies comparing a combi-
nation of interventions with no intervention. A later re-
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view15 comprising 8 studies published between 1991 and
2006 had a similar overall finding that combining psycho-
social and pharmacologic interventions resulted in better
outcomes than either no intervention or psychosocial in-
terventions alone. When this was investigated further, there
was an indication that “high intensity” smoking-cessation
counseling was more effective than “low intensity” smok-
ing-cessation counseling, although this was significant only
when provided in combination with NRT. A similar lim-
itation in that review was that motivation levels and the
reporting of the COPD severity were inconsistent. Those
authors concluded that the cessation success in this subject
group is similar to that in non-COPD trials. A major bar-
rier also was the lack of clarity over standardization of the
smoking-cessation counseling for this group, as the inter-
vention is often individualized to the patient’s needs, so it
is difficult to quantify and generalize these findings.
Objectives
The aim of this systematic review is to build on, update,
and improve the findings of the earlier reviews by Wagena
et al14 and Strassman et al,15 to identify the most effective
stop smoking intervention approach for smokers with
COPD. Changes were made to the search criteria, to iden-
tify relevant studies, such as terms to identify studies with
a psychological element to the intervention. To improve
the quality of the included studies, only those using a
biochemical validation of smoking status were included.
Methods
Criteria for Considering Studies for This Review
Types of Studies. Randomized controlled trials or quasi-
randomized controlled trials were included.
Types of Subjects. Subjects were included in the studies
if their diagnosis of COPD had been made as mild, mod-
erate, or severe after assessment using guidelines outlined
by the American Thoracic Society/European Respiratory
Society Task Force16 or National Institute for Health and
Care Excellence guidelines (2004).4 Studies that also com-
prised non-COPD diagnosed subjects in at least one com-
parison group were also included.
Types of Interventions. Studies investigating the effec-
tiveness of smoking cessation interventions in smokers
diagnosed with COPD with a minimum follow-up of
12 months after the conclusion of the intervention were
included. Smoking status at follow-up was required to be
validated using a biochemical marker, such as carbon mon-
oxide in expired breath and/or saliva/urine cotinine. The
intervention had to include a psychosocial and behavioral
support element and a standard stop smoking medication
such as NRT, bupropion, varenicline, or nortriptyline.
Types of Outcome Measures. The minimum outcome
measure for inclusion was point prevalence quit status at
12 months, with a biochemical validation.
Search Strategy to Identify Studies
Electronic databases searched were MEDLINE,
EMBASE, AMED, PsycINFO, DARE, Cochrane Library,
and CINAHL. The initial search dates for all the databases
were from January 2006 to January 2010. The references
of the included studies were screened for additional pa-
pers, and the following journals were searched by Internet
or by hand: Health Psychology, British Journal of Health
Psychology, Journal of Health Psychology, Addiction, and
Nicotine and Tobacco Research.
Search Terms. The following search terms used in the
original systematic review by Wagena et al14 were used:
COPD*, lung-diseases-obstructive*, emphysem*, bron-
chit*, tobacco, nicotine, smoking, smoking-cessation, to-
bacco-use-disorder, tobacco-smokeless, anti-smoking,
quit*, stop*, cessat*, ceas*, abstin*, abstain*, control*,
smok*, giv*, tobacco*.
The search terms used in the Strassman et al15 review
followed broader categories, due to it being part of a larger
review project on various treatments for COPD. With one
exception, these terms had been included in the Wagena
et al14 review; the one exception was “treatment outcome,”
which was considered by the authors to be too broad for
the purposes of this review.
To identify relevant studies the following additional
search terms were used: interven*, NRT, nicotine, bupro-
pion, zyban, varenicline, champix, chantix, nortript*, anti-
depress*, counsel*, behavio*, CBT [cognitive behavioural
therapy], and psycho*.
Study Selection Criteria
The search yielded 81 papers between January 2006 and
January 2010. The abstracts were read and papers not
meeting the full inclusion criteria were eliminated. This
process resulted in 4 articles that were considered relevant
for inclusion in this review.
In an attempt to expand the pool of studies for this
review, the same database search was repeated from March
2002 (the end of the journal search for the Wagena et al14
review) to December 2005, to identify any additional pa-
pers that may have been missed from the Strassman et al15
review. This yielded one additional study, but it was ex-
cluded due to the lack of a 12-month follow-up.
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Methodological Quality Assessment
A quality assessment tool was designed for this review.
In comparison to the previous 2 systematic reviews,14,15
this review did not use the full Delphi list17 to assess the
quality of the studies. The Delphi list was developed as a
minimum reference standard for randomized controlled
trials on many different research topics, and, rather than
replace, was intended to be used alongside other criteria
lists. It was felt that the subject area of this review required
an active role on the part of the subject in terms of behav-
ioral support and a degree of control over their level of
engagement with behavior change techniques. Conse-
quently, it was decided that the elements of blinding of the
care provider and the subject were not valid items, which,
as Wagena et al14 discussed, led to internal validity diffi-
culties for their systematic review when comparing psy-
chosocial interventions. To overcome this, a number of
quality assessment points were added that also aimed to
increase the validity of the studies selected.
The items in the quality assessment list and the scores
attached to each were:
• Selection Bias: How were subjects randomized? Score:
2  computer randomized, 1  other randomization,
0  no explanation
• Comparable at Baseline: Did the groups appear compa-
rable at baseline regarding the most important prognos-
tic indicators (eg, numbers smoked, addiction level, age)?
Score: 1  yes, 0  no
• Detection Bias: Was a biomarker used to validate self-
report at follow-up? Score: 2  used at  1 follow-up
point, 1  used at 1 follow-up point, 0  not used/not clear
• Detection Bias: Was a biomarker used to validate self-
report at completion of intervention? Score: 3   75%,
2  50–75%, 1   50%
• Description of Intervention Procedure: Score: 3  step-
by-step and psychological principles, 2  step-by-step,
1  some description, 0  barely any description
• Suitable Comparison Interventions (Medications): Score
2  comparable, 1  some comparison, 0  no com-
parison
• Description of Stage of Disease: Score: 1  information
given, 0  no information given
• Description of Type of Smoker (Light/Heavy): Score:
1  information given, 0  no information given
• Time Points of Follow-up: Score: 4   12 months post
intervention, 3  6–12 months post-intervention, 2 
longer than end of intervention but  6 months post-
intervention, 1  end of intervention
• Sample Size Justification: Score: 1  power calculation
used, 0  power calculation not used
• Drop-Out Rate by Conclusion of Intervention: Score:
2  drop-out rate  25%, 1  drop-out rate 25–50%,
0  drop-out rate  50% or not known
• Intention-to-Treat Analysis (Non-Attendees at Comple-
tion Classed as Smokers): Score: 1  Yes, 0  No
The selected studies were reviewed independently by 2
reviewers (GA and RP-Y). Divergence of quality assess-
ment scores was resolved by the reviewers meeting to
discuss differences in ratings and agreeing on a score.
Data Analysis
Statistical data were analyzed using statistics software
(SPSS 17, SPSS, Chicago, Illinois). The studies were het-
erogeneous with regards to:
• The study population and COPD severity: classified as
mild (FEV1  80% of predicted), moderate (FEV1 50–
79% of predicted), or severe (FEV1 30–49% of pre-
dicted), as defined by the American Thoracic Society/
European Respiratory Society (2004)16
• Format of treatment (individual, group, or telephone) or
behavioral/psychological support
• Use of pharmacologic treatments (no treatment, NRT,
bupropion)
• Level of psychological assessment, including motiva-
tion measures
• Included study quality
Significance levels, effect sizes, odds ratios, and 95% CIs
were calculated where possible, and some statistical infor-
mation in the primary research is reported where consid-
ered appropriate.
Description of Studies
Two studies were carried out in COPD out-patient clin-
ics.18,19 One study was carried out in in-patients in an
acute setting, with the control group in primary care set-
tings.20 One study was carried out in a respiratory out-
patient clinic, and the control group received no support
after initial brief advice.21 All the studies had elements of
psychological intervention. One study included group, in-
dividual, and telephone support,18 compared to a control
group with individual and telephone support. One study
offered group support, compared to a control group of
unspecified usual care.20 One study offered group support
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for both the experimental and control groups.19 And one
study comprised 2 experimental arms: one with individual
support and one with group support, plus a control group
that received no additional support after initial brief ad-
vice.21
The interventions were led by a range of healthcare
professionals, including respiratory nurses,18 a smoking
cessation nurse,20 nurse specialists trained in asthma and
COPD, a researcher trained in smoking cessation,19 and a
respiratory nurse in the experimental groups.21 In the latter
study the control group received a brief intervention from
a doctor. No information was available on the usual care
provided in primary care.20
The COPD severity was given for all subjects. All were
diagnosed using the American Thoracic Society/European
Respiratory Society16 or the National Institute for Health
and Care Excellence (2004)4 classification as mild, mod-
erate, or severe. One study comprised moderate and severe
subjects,18 2 studies comprised subjects with 3 levels of
diagnosis,20,21 and one study compared an experimental
group comprising subjects with an average mild diagnosis
to a control group of asymptomatic subjects.19
We concluded that one study gave little description of
the intervention,18 one study gave a step-by-step descrip-
tion,20 and 2 studies gave a step-by-step description and
the psychological principles.19,21
The smoking status of the subjects was measured using
a number of tools in all the studies. The cigarettes smoked
ranged from 17.5 to 24.1 per day.18,19,21 Nicotine depen-
dence, measured using the Fagerstrom Test for Nicotine
Dependence (1991), ranged from 4.7 to 4.8.20 Pack-years
(calculated as number of cigarettes smoked per day 
number of years smoked/20) ranged from 25 to 45.5.19-21
The characteristics of the studies can be found in the
supplementary materials at http://www.rcjournal.com.
Methodological Quality
The quality scores of the studies range from 11 to 20.
One study used a computer-generated list of random num-
bers,21 one study was randomized according to other cri-
teria (eg, the level of COPD),19 and 2 studies gave no
explanation.19,20 Biomarker validation was used for  75%
of outcomes in 3 studies, using a range of measures: sal-
ivary cotinine test ( 20 ng/mL),18 urinary cotinine with a
cutoff set at  25 ng/mL,19 and in one of these studies 2
measures were used: expired breath carbon monoxide with
a cutoff at  10 parts per million, and salivary cotinine
with a cutoff level of  10 ng/mL,21 and less than 50% in
one study using expired breath carbon monoxide monitor-
ing with a cutoff set at  8 parts per million.20 Two
studies19,21 used biomarkers on more than one follow-up,
one study18 used biomarkers on one follow-up, and one
study20 did not use a biomarker until the end of the study.
Only one study21 included a sample size justification or
power analysis, yet failed to achieve the sample size re-
quired. Two studies had  100 subjects in each group,18,20
and 2 studies had  40 subjects per group.19,21 Two stud-
ies had a drop-out rate of  25%,19,20 while 2 studies had
drop-out rates of 25–50%.18,21 Explanations for these drop-
outs were not consistently reported (see the supplementary
materials at http://www.rcjournal.com).
Results
The primary aim of the 4 studies identified for this
review was the effect of the interventions on smoking
cessation. The supplementary materials at http://www.
rcjournal.com show the outcomes of the studies included
in this review. A meta-analysis was also conducted (see
the supplementary materials at http://www.rcjournal.com).
All 4 measured abstinence 12 months post-intervention.
Just one19 reported follow-up outcomes at points before
this, while one reported follow-up outcomes 24 months
after this point. The results for the 12 months will be
reported and the results at 36 months follow-up will be
discussed in the context of that study. The overall differ-
ence in the effectiveness of all the studies at 12 months
between the experimental groups and the control groups
was significant (chi-square test for heterogeneity chi-
square  39.7, P  .001), with a total of 35.5% of subjects
quitting smoking in the experimental groups, and 10%
quitting smoking in the control groups (pooled random-
effects odds ratio 2.35, 95% CI 0.25–21.74). A by-studies
comparison showed: in Sundblad et al20 there were similar
numbers of subjects in the experimental and control groups
(n  204 and 219, respectively); in Christenhusz et al18
there were more subjects in the experimental group (n  96,
compared to n  67 in the control group); in Willemse et
al19 there were more subjects in the experimental group
(n  38, compared to n  25 in the control group).
Different Psychosocial Interventions
With Pharmacotherapy
Christenhusz et al18 compared 2 interventions with sub-
jects diagnosed with either moderate or severe COPD. One
group received 595 min of support (high intensity), al-
though the number of sessions was not stated. Delivered in
group, individual, and telephone format, 100% were pre-
scribed bupropion free of charge, and 6% also reported
using NRT. The control group received 180 min (medium
intensity) of individual and telephone support, although
again it was not reported over how many sessions. In this
study 28% used bupropion and 14% used NRT, although
these were not free of charge. Respiratory nurses delivered
both interventions. At 12 month follow-up 19% were ab-
stinent in the experimental group and 9% were abstinent in
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the control group (odds ratio 2.35, 95% CI 0.88–6.27).
The high intensity group had a higher nicotine addiction
score, measured by Fagerstrom (59%, compared to 42%
scoring  6). Other independent variables measured in-
cluded attitude to smoking cessation, self efficacy, and
quality of life, although changes in these were nonsignif-
icant (P  .08) in the experimental group. For the control
group a higher cotinine value at baseline led the authors to
indicate that each rise of 100 ng/mL doubled the likeli-
hood of quitting and that a positive attitude toward stop-
ping success increased by 12 times (both variables P 
.003). However, a large confidence interval of the odds
ratio was reported (odds ratio 22.52, 95% CI 1.55–327.97),
which indicates low precision in this estimate.
Sundblad et al20 compared a high intensity in-patient
intervention with usual care provided in primary care health
centers. A smoking cessation nurse delivered the experi-
mental arm for 1 hour per day in groups of 4–8 people
over 11 days, as part of a wider lifestyle intervention with
additional input from a doctor, a physiotherapist, a dieti-
tian, a laboratory technician, a psychologist, an occupa-
tional therapist, and a nurse. NRT was recommended, and
was used by 28% in the experimental group and 14% in
the control group. There were also regular follow-up tele-
phone calls for 2–3 months after discharge, and the subject
and his or her spouse then returned for 2–4 days as in-
patients, followed by additional telephone support fol-
low-up until 12 months post-intervention. No information
was given on the usual care offered for the control group,
although just 20% (46) accessed this. At 1 year, point
prevalence abstinence (in the previous 6 months) was sig-
nificant (chi-square  105.2, P  .001), with 52% in the
intervention group and 7% in the control stopping (odds
ratio 14.71, 95% CI 8.14–26.59). At 3 years these figures
had reduced to 38% and 10%, respectively, but the treat-
ment difference was still significant (chi-square  44.0,
P  .001). There was no difference in outcome based on
the severity of the disease. There were no differences re-
ported in nicotine dependence between the groups at base-
line, although the authors acknowledged that which part of
the intervention was effective is difficult to deduce, given
the mixed use of pharmacotherapy and the extensive for-
mat of the wider intervention.
Wilson et al21 compared a high intensity individual in-
tervention and a high intensity group intervention (5 ses-
sions of 1 hour each) provided by one respiratory nurse
and 2 respiratory nurses, respectively, (including an initial
5–10 min brief intervention) with an individual usual care,
brief intervention (5–10 min) only, delivered by a doctor,
in an out-patient department. The experimental arms also
offered 12 weeks of NRT, while no information is avail-
able for the control group. No quitters were reported in
either group at 12 month follow-up, so no effect size was
calculated. However, it was reported that all groups had a
significant reduction in nicotine addiction over this period:
P  .006 between the control and group intervention, and
P  .03 between the control and individual support.
Comparison By Disease Presence
Willemse et al19 studied a group intervention (8–10 per
group) in an out-patient setting. The experimental group
had been diagnosed with mild COPD and the control group
was asymptomatic. A respiratory nurse specialist and a
researcher trained in smoking cessation delivered the same
intervention. Nine 2-hour sessions were initially offered
over 6 weeks. Based on programs developed in the Neth-
erlands, they incorporated cognitive behavioral therapy
techniques to build motivation, and self-efficacy and cop-
ing skills. Additional telephone support was offered in
between sessions, and 6 additional group sessions were
offered, ad hoc, over the remaining time to 12 months,
provided by the same facilitators. No pharmacotherapy
was recommended. At 12 months, continual abstinence
was significant (chi-square  4.05, P  .05), although
with 42% in the intervention group and 68% in the control
group, so the control group was more successful (odds
ratio 0.34, 95% CI 0.12–0.99).
Discussion
The heterogeneity between studies with respect to pop-
ulations and interventions, combined with few studies with
relatively few subjects, meant that any estimation of an
effect size was bound to be uncertain. So, although the
intervention looked promising, it is not possible on current
evidence to quantify the effect or confirm that the prom-
ising results observed are not the result of chance. Further,
odds ratios, while widespread, are problematic as effect
size measures when the frequency of the outcome is high.
Disease Severity
Subjects with different COPD severity within and be-
tween each study make clear conclusions difficult. There-
fore, as was also recommended in the Wagena et al22
review, sub-analysis would be preferable wherever possi-
ble (eg, as in Sundblad et al20).
The time since diagnosis was not reported, which could
impact the subject’s perception of their smoking behavior
and its impact on their illness and development of coping
strategies to live with and manage exacerbations. A future
study could therefore investigate the effect of time from
diagnosis on smoking cessation outcomes as another in-
clusion criterion.
It is important to highlight that, given that one of the
studies contained a control group with non-COPD patients,
the estimated effect sizes may not be generalizable.
SMOKING CESSATION INTERVENTIONS FOR COPD: A REVIEW OF THE LITERATURE
1960 RESPIRATORY CARE • NOVEMBER 2013 VOL 58 NO 11
Levels of Addiction and Intensity of Intervention
Consistent reporting according to disease severity would
help clarify the effects of level of addiction and intensity
of interventions, as illustrated by 2 of the studies. Higher
cotinine levels resulted in a better outcome, contrary to
popular assumptions regarding level of addiction and suc-
cessful quitting,18 leading to the suggestion that the higher
intensity compensates for higher addiction in one group,
while a higher favorable attitude score to cessation found
in the less intense control could compensate for the higher
addiction. One hypothesis by the authors is that smokers
with a high cotinine level may have a more internal mo-
tivation, as they may experience worse symptoms, whereas
those with a lower cotinine level may have a more exter-
nal, less stable motivation (eg, being advised to stop by a
practitioner). In another study19 the intervention group had
mild COPD but higher pack-years than the control group.
The high quit rate in both groups was thought to be pos-
sibly due to high contact time and intense baseline and
follow-up measurements, with frequent and intensive mo-
tivational support being proposed to account for the high
cessation rate, suggesting a flexible approach to cessation,
with interventions designed depending on initial findings
of screening.
Effect of Healthcare Professional
As found by the Strassman et al15 review, there were a
number of points in the studies in this review when the
person delivering the intervention could have affected the
intervention, for example during ad hoc telephone support.
This additional support could offer an opportunity for re-
lapse prevention, but its lack of measurement can make it
more difficult to generalize the findings.
Attendance
Poor attendance was an issue for usual care condi-
tions.20,21 Wilson et al21 recommend that research inves-
tigates more acceptable interventions or that their study is
repeated in a community setting. In comparison, Willemse
et al19 found that a medical setting may have had an effect
on their study, hypothesizing that the medical research
environment may have made the subjects feel more re-
sponsible for the outcome. This may have made subjects
more serious toward the intervention, questioning the bal-
ance between “medicalizing” an intervention and ease of
access in a community setting. The effect of exacerbations
during the studies was not measured. These could affect
attendance and adherence to the use of stop smoking med-
ications, and it could be hypothesized that they may be
more likely to attend a medical setting during such epi-
sodes. Additional information on the health of the subjects
during the course of the studies would be useful.
Social Support and Motivation
Social circumstances should also be considered. Wilson
et al21 reported that 42% lived with a smoker, and this may
have affected their perception of the importance of cessa-
tion, or they may not have received the peer support that
could have effected a successful outcome. Similarly, mo-
tivation of subjects to take part was not measured consis-
tently and varied from a measured “stage of change” iden-
tification to being estimated by their attendance at an
information session and the signing of an informed con-
sent form as a proxy measure for motivation.18,20 Poorer
outcomes could possibly be a function of the subject se-
lection; at recruitment a number of the studies indicated
that a high proportion of the subjects had already quit
smoking, leaving a potential sub-group who could be de-
scribed as “recalcitrant” smokers.
Follow-up and Biomarkers
It is acknowledged that a large percentage of the general
population relapse within the first 12 months post-quitting.
For a complex group such as COPD patients this could
therefore be considered too long a period as a measure and
also to indicate that the level of initial support, or fol-
low-up relapse prevention support, is not sufficient, as the
aim of stop smoking interventions is to provide smokers
with the skills to maintain abstinence.
Three out of the 4 studies used continuous abstinence as
a measure, while one study used a long duration point
prevalence marker of 6 months. Van der Meer et al23 rec-
ognized that, based on the findings of Velicer et al,24 a
combination of continuous abstinence and point preva-
lence measures should be used to assess outcomes to reach
a clearer picture of the quitting process. Although not used
by the studies under review, this would illustrate the dy-
namic nature of smoking cessation. Point prevalence would
raise quit rates in the short-term, increasing self-efficacy in
that subjects can stop rather than being labeled a “failure”
for not achieving continuous abstinence status, while con-
tinuous abstinence would help to identify better assess-
ment of the longer-term effects of an intervention.
Conclusions
The primary aim of the studies identified in this review
was to establish the effectiveness of psychosocial inter-
ventions, with the effect of pharmacotherapy being a sec-
ondary outcome. It has been difficult to establish the most
effective approach to smoking cessation to take with a
COPD population. Despite stricter inclusion criteria, there
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were still many differences in the composition and level of
intensity of interventions and the subjects themselves. The
outcome of quit/not quit does not appear to allow suffi-
cient scope for measuring the effect of the constituent
parts of a psychosocial intervention. Without this better
measurement, biomedical approaches may appear more
effective; for example, Bittoun25 found that more NRT use
without explicit psychosocial intervention can be very ef-
fective at achieving a non-smoking status for this group. In
this review there was no consistent use of or access to stop
smoking pharmacotherapies, which could obscure the ef-
fects of the psychological components of the interventions
under review.
However, consistent with Strassman et al,15 a combina-
tion of pharmacotherapy and psychosocial support appears
to be the best approach to take to stopping smoking, al-
though a lengthy intervention does not necessarily result in
better outcomes. Locating the interventions in a medical
setting does appear to have a positive impact on initiation
of a treatment, and may be a method of improving ongoing
engagement with support services, in comparison to stan-
dard usual care services in primary care or community
settings.
This review highlights the challenge for future research
to develop more tailored interventions to reduce smoking
prevalence in a chronic clinical population where a range
of behavior changes is essential to managing their health
and improving well-being.
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